2/20
07:27 am
atrc
AtriCure (NASDAQ:ATRC) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
AtriCure (NASDAQ:ATRC) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
2/18
10:10 am
atrc
AtriCure (NASDAQ:ATRC) was given a new $53.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
AtriCure (NASDAQ:ATRC) was given a new $53.00 price target on by analysts at Canaccord Genuity Group Inc..
2/18
10:10 am
atrc
AtriCure (NASDAQ:ATRC) was given a new $55.00 price target on by analysts at UBS Group AG.
Low
Report
AtriCure (NASDAQ:ATRC) was given a new $55.00 price target on by analysts at UBS Group AG.
2/18
09:37 am
atrc
AtriCure (NASDAQ:ATRC) had its price target lowered by analysts at Citizens Jmp from $60.00 to $52.00. They now have a "market outperform" rating on the stock.
Low
Report
AtriCure (NASDAQ:ATRC) had its price target lowered by analysts at Citizens Jmp from $60.00 to $52.00. They now have a "market outperform" rating on the stock.
2/18
08:13 am
atrc
AtriCure (NASDAQ:ATRC) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $54.00 price target on the stock.
Medium
Report
AtriCure (NASDAQ:ATRC) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $54.00 price target on the stock.
2/18
08:06 am
atrc
AtriCure (NASDAQ:ATRC) was given a new $44.00 price target on by analysts at Oppenheimer Holdings, Inc..
Medium
Report
AtriCure (NASDAQ:ATRC) was given a new $44.00 price target on by analysts at Oppenheimer Holdings, Inc..
2/18
07:01 am
atrc
AtriCure (NASDAQ:ATRC) was downgraded by analysts at Oppenheimer Holdings, Inc. from an "outperform" rating to a "market perform" rating.
Medium
Report
AtriCure (NASDAQ:ATRC) was downgraded by analysts at Oppenheimer Holdings, Inc. from an "outperform" rating to a "market perform" rating.
2/18
07:01 am
atrc
AtriCure (NASDAQ:ATRC) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
AtriCure (NASDAQ:ATRC) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
2/18
12:19 am
atrc
AtriCure Inc (ATRC) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
High
Report
AtriCure Inc (ATRC) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
2/17
07:18 pm
atrc
AtriCure Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
AtriCure Q4 Earnings Call Highlights [Yahoo! Finance]
2/17
06:40 pm
atrc
AtriCure (ATRC) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
AtriCure (ATRC) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/17
04:37 pm
atrc
AtriCure: Q4 Earnings Snapshot [Yahoo! Finance]
High
Report
AtriCure: Q4 Earnings Snapshot [Yahoo! Finance]
2/17
04:01 pm
atrc
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
Low
Report
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
2/12
08:04 am
atrc
AtriCure (NASDAQ:ATRC) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
Low
Report
AtriCure (NASDAQ:ATRC) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
2/11
08:00 am
atrc
AtriCure (NASDAQ:ATRC) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $36.00 price target on the stock.
Medium
Report
AtriCure (NASDAQ:ATRC) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $36.00 price target on the stock.
1/27
08:00 am
atrc
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
Low
Report
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
1/23
05:06 am
atrc
AtriCure (NASDAQ:ATRC) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
AtriCure (NASDAQ:ATRC) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/12
10:32 am
atrc
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 [Yahoo! Finance]
Medium
Report
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 [Yahoo! Finance]
1/12
10:21 am
atrc
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
Medium
Report
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
12/25
07:32 pm
atrc
AtriCure (ATRC): Assessing Valuation After First-In-Human PFA/RFA Procedures and Renewed Analyst Optimism [Yahoo! Finance]
Low
Report
AtriCure (ATRC): Assessing Valuation After First-In-Human PFA/RFA Procedures and Renewed Analyst Optimism [Yahoo! Finance]
12/25
07:32 am
atrc
Assessing AtriCure's Valuation After a 33.4% Rally in 2025 [Yahoo! Finance]
Low
Report
Assessing AtriCure's Valuation After a 33.4% Rally in 2025 [Yahoo! Finance]
12/23
03:17 pm
atrc
Analysts See an Over 26% Upside in AtriCure (ATRC) [Yahoo! Finance]
Low
Report
Analysts See an Over 26% Upside in AtriCure (ATRC) [Yahoo! Finance]
12/17
08:00 am
atrc
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
Low
Report
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
12/16
10:45 am
atrc
AtriCure (NASDAQ:ATRC) had its price target raised by analysts at JPMorgan Chase & Co. from $42.00 to $48.00. They now have an "overweight" rating on the stock.
Low
Report
AtriCure (NASDAQ:ATRC) had its price target raised by analysts at JPMorgan Chase & Co. from $42.00 to $48.00. They now have an "overweight" rating on the stock.
12/13
02:18 pm
atrc
AtriCure (ATRC) Is Up 6.3% After Dual Energy PFA–RFA First-in-Human Success - Has The Bull Case Changed? [Yahoo! Finance]
Medium
Report
AtriCure (ATRC) Is Up 6.3% After Dual Energy PFA–RFA First-in-Human Success - Has The Bull Case Changed? [Yahoo! Finance]